Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY21 Earnings Presentation
13 slides from Eris Lifesciences's earnings presentation, Jan 28, 2021
Slide 1: Exchange filing intimation letter for investor presentation
Date: 28th January, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the req
Slide 2: Eris Lifesciences Ltd Q3 FY21 Investor Presentation
ERIS LIFESCIENCES LTD Q3 FY 21 INVESTOR PRESENTATION 1
Slide 3: Q3 FY21 – Market Leading Growth
Q3 FY 21 – MARKET LEADING GROWTH Eris among the fastest growing companies in IPM (excl. Covid Molecules) Q3 FY 21 yoy growth: IPM excluding Covid Molecules 15.6% 15.5% 13.7% 12.4% 11.5% 10.4% 10.1% 9.2% 7.8% 7.7% 5.0% IPM excl. Eris Cadila Emcure IPCA Sanofi USV Cipla Intas Torrent Lupin Covid Molec
Slide 4: Q3 FY21 – Business Highlights
Q3 FY 21 – BUSINESS HIGHLIGHTS • Continued super-specialty focus and relentless execution leads to 10th consecutive quarter of outperforming covered market in core Cardio metabolic and VMN segments (≈ 78% of sales) Cardio Metabolic VMN 17.0% 13.6% 39.3% 12.9% 12.2% 12.0% 12.0% 11.1% 8.1% 13.6% 15.7%
Slide 5: Power Brands Continue to Have Leading Presence in Core Therapies
Q3 FY 21 – POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in new generation fast growing molecules Sulfonylurea Glimisave rank 5 in the ≈4,500 cr Glimepiride and combinations market Glimisave MV rank 2
Slide 6: Power Brands Continue to Have Leading Presence in Core Therapies
Q3 FY 21 – POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES High rank in Anti-Hypertensives: the fastest growing and largest segment of Cardiac Care Eritel rank 5 in the ≈3,500 cr Telmisartan and combinations market Eritel CH rank 4 in Telmisartan + Chlorthalidone market Eritel LN ra
Slide 7: Tailwinds from Prescription Trends and Patent Expirations
Q3 FY 21 – TAILWINDS FROM PRESCRIPTION TRENDS AND PATENT EXPIRATIONS Eris’s tailwinds for long-term sustainable growth: • Prescriber preference seen shifting towards established incumbent brands during the last 9 months; this bodes well for Eris with 11 of its Top 15 mother brands being ranked among
Slide 8: Key Financial and Corporate Highlights
Q3 FY 21 – KEY FINANCIAL AND CORPORATE HIGHLIGHTS Q3 FY 21 16.5% 39.7% 42.0% yoy growth Op Revenue EBITDA PAT 9m FY 21 13.1% 15.4% 19.4% yoy growth Op Revenue EBITDA PAT • Working Capital Management – Reduction in Debtor Days tracking in line with guidance • Raising the bar on Corporate Governance –
Slide 9: Standalone Income Statement
Q3 FY 21 – STANDALONE INCOME STATEMENT Standalone Q3 FY 21 9m FY 21 INR Millions Q3 FY 21 Q3 FY 20 9m FY 21 9m FY 20 yoy GR yoy GR Sale of Products 2,815 2,495 12.8% 8,360 7,777 7.5% Other Operating Income 56 48 17.9% 160 118 35.5% Revenue from Operations 2,871 2,543 12.9% 8,520 7,895 7.9% Gross Pro
Slide 10: Consolidated Income Statement
Q3 FY 21 – CONSOLIDATED INCOME STATEMENT Consolidated Q3 FY 21 9m FY 21 INR Millions Q3 FY 21 Q3 FY 20 9m FY 21 9m FY 20 Q3 FY 21 yoy GR yoy GR Break up of Consolidated Sale of Products Q3 FY 21 Q3 FY 20 yoy GR Sale of Products 3,050 2,618 16.5% 9,184 8,141 12.8% Other Operating Income 54 46 15.8% 1
Slide 11: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, DIIs 0.73% As on As on As on Name of Shareholder 10.90% 31-Dec-20 30-Sep-20 30-Jun-20 579.95* 538.2* 457.3* Promoters 54.23% 54.08% 55.55% FPI 1 ChrysCapital (Emerald Investment Limited) 5.51% 5.51% 5.51% 11.13%
Slide 12: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 13: Thank You
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 12